They cited the need for a CD4 ‘baseline’ for patients initiating ART and they felt that ongoing CD4 monitoring was required to measure the need for OI (opportunistic infection) prophylaxis, ART response and a switch in treatment regimens. The gene discussed is CD4; the disease is Opportunistic infection.